Physicians' Academy for Cardiovascular Education

Triglycerides

Why focus on triglyceride-rich lipoproteins and their remnants?

10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Highly purified EPA reduces important ischemic events in hypertriglyceridemia

3' education - Nov. 11, 2018 - Deepak Bhatt, MD - Boston, MA, USA.
##SCROLLER_ITEMS_FULL_TITLE##

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
##SCROLLER_ITEMS_FULL_TITLE##

Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton
##SCROLLER_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

Hypertriglyceridemia: New small-molecule based strategies

10' education - Oct. 1, 2014 - Barcelona - Christie Ballantyne MD

Phase 2b trial evaluating ANGPTL3 antisense meets primary endpoint

News - Nov. 29, 2021

The TRANSLATE-TIMI 70 trial, a dose-ranging phase 2b study with the ANGPTL3 antisense vupanorsen in subjects with dyslipidemia, met its primary endpoint: a significant reduction of non-HDL-c at 24 weeks with vupanorsen compared to placebo.

Why focus on triglyceride-rich lipoproteins and their remnants?

10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD
What are triglyceride-rich lipoprotein (TGRL) remnants? How do TGRL remnants differ from LDL and do these differences make them more atherogenic? Prof. Henry Ginsberg answers these questions in this video.

What are triglyceride-rich lipoprotein (TGRL) remnants? How do TGRL remnants differ from LDL and do these differences make them more atherogenic? Prof. Henry Ginsberg answers these questions in this video.

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME
What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.

What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.

E-learning Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Many questions remain on the subject of triglycerides, EPA-based therapies and CV outcomes. Three discussants attempt to unravel the mysteries in this field.

Triglyceride-rich lipoproteins and residual CV risk

Subtitling in English, German, Italian, Spanish, Chinese and French

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD
It is relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.

It is relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME
Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.

Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME
What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.

What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.

ESC debate | Do patients benefit from omega-3 fatty acids?

News - Sep. 7, 2021
Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

Consensus recommendations for ASCVD risk reduction in hypertriglyceridemia

News - Aug. 10, 2021

The ACC has published an Expert Consensus Decision Pathway which provides practical recommendations on lifestyle modifications in patients with hypertriglyceridemia and use of statins and TG risk-based non-statin therapies for ASCVD risk reduction.

Omega-3 fatty acids supplementation associated with increased risk of incident AF

Literature - June 15, 2021 - Lombardi M et al. - Eur Heart J Cardiovasc Pharmacother. 2021

This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.

Icosapent ethyl reduces whole-heart coronary atherosclerotic plaque burden

News - May 31, 2021

ACC 2021 This subanalysis of the EVAPORATE trial showed a significant reduction in whole-heart atherosclerotic plaque burden over 18 months in statin-treated patients with elevated triglyceride levels who received icosapent ethyl compared to those on placebo.

TG reduction with ANGPTL3 antibody in patients with severe hypertriglyceridemia

News - May 19, 2021

ACC 2021 A phase 2 study showed that evinacumab resulted in reduction of TGs in patients with severe hypertriglyceridemia, but lowering was variable and dependent on genotype.